Hospital
Jordan Valley Medical Center LP
Jordan Valley Medical Center LP was paid $15.57M by Medicaid between Jan 2018 and Aug 2023, across 154 billing codes. Its largest line is 8888888, Internal/system code - not a standard HCPCS code — 75% of everything it billed.
33Billing provider infoJORDAN VALLEY MEDICAL CENTER LP
WEST VALLEY CITY, UT 84120
WEST VALLEY CITY, UT 84120
33aNPI1366440620assigned 07/11/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$15.57M
24GClaims265,228
24DCodes billed154
24AFirst – last monthJan 2018 – Aug 2023
Compared with peers
Next to other General Acute Care Hospital providers in Utah
Rank by total paid#6 of 26
Median peer was paid$6.14M
This provider vs. median2.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 53,326 | $2.82M | |
| 2019 | 43,731 | $2.46M | |
| 2020 | 46,027 | $2.95M | |
| 2021 | 63,759 | $3.71M | |
| 2022 | 55,620 | $3.47M | |
| 2023 | 2,765 | $145K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 8888888 | Internal/system code - not a standard HCPCS code | 75% | 46,194 | 17,266 | $11.63M |
| 36415 | Collection of venous blood by venipuncture | 12% | 18,111 | 14,774 | $1.93M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.6% | 9,185 | 8,581 | $402K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.0% | 1,724 | 1,625 | $319K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | <1% | 9,938 | 9,115 | $140K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,301 | 1,260 | $85K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,329 | 2,125 | $75K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,997 | 1,868 | $62K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,340 | 2,209 | $60K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 7,255 | 6,516 | $54K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,071 | 1,028 | $47K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,248 | 7,246 | $46K |
142 more codes
| 81003 | <1% | 3,567 | $43K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,001 | $43K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,736 | $40K |
| 87631 | <1% | 581 | $33K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,144 | $32K |
| 81001 | <1% | 6,317 | $32K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 688 | $31K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 518 | $29K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,009 | $29K |
| 84703 | <1% | 3,534 | $21K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,030 | $21K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,594 | $18K |
| 80053 | Comprehensive metabolic panel | <1% | 12,046 | $17K |
| 81002 | <1% | 209 | $17K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,988 | $16K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 680 | $14K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,462 | $13K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,407 | $13K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 516 | $12K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,170 | $11K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,122 | $11K |
| 73610 | <1% | 103 | $10K | |
| 73562 | <1% | 190 | $9K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 124 | $9K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,659 | $9K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,730 | $9K |
| 87077 | <1% | 702 | $8K | |
| 87088 | <1% | 1,089 | $8K | |
| 80050 | General health panel | <1% | 1,896 | $7K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 17 | $7K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 210 | $7K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,266 | $6K |
| 73630 | <1% | 111 | $6K | |
| 81025 | <1% | 858 | $6K | |
| 82962 | <1% | 1,176 | $6K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 54 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 835 | $5K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,713 | $4K |
| 73030 | <1% | 68 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 334 | $4K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,094 | $4K |
| 86710 | <1% | 57 | $4K | |
| 84484 | <1% | 3,550 | $4K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 49 | $4K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 28 | $3K |
| 87081 | <1% | 128 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 448 | $3K |
| 94760 | <1% | 1,522 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,548 | $3K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 45 | $3K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 136 | $3K |
| 73110 | <1% | 45 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,918 | $3K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,280 | $3K |
| 85610 | <1% | 1,355 | $3K | |
| 83690 | <1% | 4,951 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 68 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,390 | $2K |
| 83880 | <1% | 1,041 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 201 | $2K |
| 72100 | <1% | 40 | $2K | |
| 59025 | Fetal non-stress test | <1% | 390 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,557 | $2K |
| 80329 | <1% | 377 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,979 | $2K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 210 | $2K |
| 31720 | <1% | 55 | $2K | |
| 80320 | <1% | 683 | $2K | |
| G0378 | Hospital observation service, per hour | <1% | 353 | $1K |
| 73130 | <1% | 36 | $1K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 170 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,043 | $1K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,376 | $1K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 56 | $1K |
| A9270 | Non-covered item or service | <1% | 5,181 | $1K |
| 94761 | <1% | 119 | $1K | |
| 96376 | <1% | 1,446 | $857.23 | |
| 80179 | <1% | 603 | $736.46 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 340 | $625.47 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 119 | $625.29 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,190 | $566.21 |
| 82947 | <1% | 90 | $498.75 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,775 | $476.01 |
| 83605 | <1% | 2,359 | $443.47 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,014 | $440.79 |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 253 | $436.97 |
| 85379 | <1% | 1,018 | $372.50 | |
| 82550 | <1% | 39 | $353.71 | |
| 84439 | <1% | 248 | $349.07 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 14 | $334.97 |
| 73502 | <1% | 15 | $280.03 | |
| 87186 | <1% | 806 | $266.20 | |
| 87040 | <1% | 548 | $237.26 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 12 | $172.74 |
| 85730 | <1% | 119 | $163.02 | |
| 84702 | <1% | 583 | $149.92 | |
| 74018 | <1% | 29 | $140.44 | |
| 80061 | Lipid panel | <1% | 777 | $139.82 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 272 | $106.69 |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 112 | $89.89 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 573 | $51.26 |
| 85027 | <1% | 657 | $40.09 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 40 | $30.44 |
| 87503 | <1% | 118 | $26.78 | |
| 80143 | <1% | 603 | $25.04 | |
| J3490 | Unclassified drugs | <1% | 215 | $24.58 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 570 | $23.31 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 13 | $12.50 |
| 86901 | <1% | 357 | $12.13 | |
| 82805 | <1% | 29 | $10.13 | |
| 83735 | <1% | 207 | $9.83 | |
| 86140 | <1% | 110 | $9.35 | |
| 86900 | <1% | 357 | $8.61 | |
| 82077 | <1% | 798 | $8.10 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 118 | $6.41 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 511 | $6.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 450 | $5.11 |
| 85652 | <1% | 81 | $2.52 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 77 | $0.00 |
| 88342 | 0% | 51 | $0.00 | |
| 82553 | 0% | 12 | $0.00 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 195 | $0.00 |
| 94762 | 0% | 94 | $0.00 | |
| 70486 | 0% | 15 | $0.00 | |
| 86850 | 0% | 87 | $0.00 | |
| 86762 | 0% | 13 | $0.00 | |
| 86308 | 0% | 59 | $0.00 | |
| 86592 | 0% | 31 | $0.00 | |
| 82950 | 0% | 13 | $0.00 | |
| 85651 | 0% | 13 | $0.00 | |
| 87340 | 0% | 14 | $0.00 | |
| 84436 | 0% | 27 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 13 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 77 | $0.00 |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 13 | $0.00 |
| 85007 | 0% | 66 | $0.00 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 0% | 13 | $0.00 |
| A4649 | Surgical supply; miscellaneous | 0% | 53 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 33 | $0.00 |
| 90715 | 0% | 14 | $0.00 | |
| 86703 | 0% | 15 | $0.00 | |
| 86787 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, STEVEN (HOSPITAL CEO)
| Provider | Location | Paid |
|---|---|---|
| Jordan Valley Medical Center LP | West Jordan, UT | $9.07M |
| Jordan Valley Medical Center LP | West Jordan, UT | $7.27M |
| Jordan Valley Medical Center LP | Lehi, UT | $5.61M |
| Americare Assisted Living, INC | Deltona, FL | $1.41M |
| Jordan Valley Medical Center LP | West Valley City, UT | $65K |
| Crowders Neighborhood Drug Store INC | Bedford, IN | $27K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.